Ask AI
ProCE Banner Activity

 A Novel 2-Drug Combination Therapy for ART Simplification

Clinical Thought

Contemporary HIV care requires us to balance durable viral suppression with long-term tolerability and simplicity for maintaining adherence and quality of life. However, for individuals with multidrug-resistant HIV, the choice of ART regimen can be more complex. Read the latest on a potential emerging option.

Released: April 15, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with American Academy of HIV Medicine, Association of Nurses in AIDS Care (ANAC), and HealthHIV

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Partners

American Academy of HIV Medicine

ProCE Banner

ANAC

ProCE Banner

HealthHIV

ProCE Banner

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and advanced practice professionals who provide HIV care in specialist or primary care settings.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate data on newer and emerging options for HIV care into management strategies

  • Adopt strategies for the use of ART that align with new evidence and guideline recommendations

Disclosure

Primary Author

Chloe Orkin, MBChB, FRCP, MD: consultant/advisor/speaker: Gilead, GSK, Merck Sharp & Dohme, ViiV.